RxDoctor Payments Data

Raees Ahmed, MD

Psychiatry · Sugar Land, TXNPI 1013180793

Payments from drug & device makers

$554in general payments, 2019–2025

Across 23 payments — averaging $24.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$163
  • Indivior Inc.$145
  • Neurocrine Biosciences, Inc.$70
  • AbbVie$50
  • Almatica Pharma LLC$35
  • Lundbeck LLC$23
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$554100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$554 in reported general payments places this provider in the 60th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$14,788
Medicare patients
37
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate35$96,773
RexultiBrexpiprazole12$14,759
Lurasidone Hcl22$14,034
Aripiprazole70$7,884
Paliperidone ErPaliperidone15$2,361
Quetiapine Fumarate139$2,314
Hydroxyzine Hcl68$1,376
Atomoxetine Hcl14$1,363
Clonazepam157$1,132
Buspirone Hcl123$1,037
Oxcarbazepine38$999
Trazodone Hcl208$917
Duloxetine Hcl79$852
Risperidone83$843
Bupropion XlBupropion Hcl52$843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$163$96,77335 claims
Otsuka America Pharmaceutical, Inc.Rexulti$17$14,75912 claims
Almatica Pharma LLCSertraline Hcl$35$23899 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →